Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Drug clinical trials: the CTIS portal becomes the sole entry point for new requests as of the 31st of January 2023

https://ansm.sante.fr/actualites/essais-cliniques-medicaments-le-portail-ctis-devient-lunique-point-dentree-pour-les-nouvelles-demandes-au-31-janvier-2023?fbclid=IwAR1Iw2CrNskojkz-AQ-WTsgdS4DE4LkvlQShsXdm2jXeFdrvQ_RwUGvWJoc

Ryan McArthur 2 February 2023 All news
  • ← Work Plan 2023 of the Pharmacovigilance Risk Assessment Committee (PRAC)
  • The European Medicines Agency (EMA) is delivering a Product Management Service (PMS) and a Substance Management Service (SMS) to support regulatory activities in the European Union (EU) →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • European regulation on clinical trials for medicinal products: The end of the transition period
  • The ANSM publishes its haemovigilance report for 2023
  • User’s booklet – ANSM
Copyright © 2018 - Pharmya - Legal terms - Quality Policy